Aytu Biopharma (AYTU) Non-Current Debt (2020 - 2026)

Aytu Biopharma (AYTU) has 7 years of Non-Current Debt data on file, last reported at $9.5 million in Q1 2026.

• Non-Current Debt for Q1 2026 came in at $9.5 million, changed 0.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.5 million (changed 0.15% YoY), and the FY2025 annual result was $10.9 million, changed 0.17% from the prior year.
• Non-Current Debt retreated to $9.5 million in Q1 2026 per AYTU's latest filing, from $10.0 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $15.0 million in Q4 2023 and troughed at $9.5 million in Q1 2025.
• A 5-year average of $12.1 million and a median of $11.1 million in 2023 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2022 and 2024: Non-Current Debt soared 11165.89% in 2022, then tumbled 33.35% in 2024.
• A 5-year view of Non-Current Debt shows it stood at $14.5 million in 2022, then gained by 3.06% to $15.0 million in 2023, then plunged by 33.35% to $10.0 million in 2024, then grew by 0.15% to $10.0 million in 2025, then declined by 4.49% to $9.5 million in 2026.
• Business Quant data shows AYTU's Non-Current Debt at $9.5 million in Q1 2026, $10.0 million in Q4 2025, and $10.4 million in Q3 2025.